

Preventative Health Visit (Annual Female Exam) – HM 2

DEFINITION

A medical visit that involves screening, evaluation, counseling, and education based on age and risk factors. Related preventative health services include services that are beneficial to reproductive health, are closely linked to family planning services, and are appropriate to deliver in the context of a family planning visit but do not contribute directly to achieving or preventing pregnancy (e.g., breast and cervical cancer screening). The annual exam includes preventative health services in accordance with nationally recognized standards of care. A preventative health visit is not a requirement for provision of any core family planning services.

SUBJECTIVE

Should include:

1. Medical history, including cervical cytology history as indicated
2. Pertinent family history
3. Reproductive life plan
4. Client pregnancy status
5. Sexual health assessment
6. Substance use assessment

May Include as indicated:

1. Assessment for intimate partner violence
2. Immunization review
3. Depression screening
4. Folic acid use
5. Review of systems

OBJECTIVE

Should include:

1. Height, weight with calculation of BMI and blood pressure
2. Pelvic exam if initiating a diaphragm or IUD for contraception, or performing screening for cervical or vulvar malignancy

May Include as indicated:

1. Pelvic exam- It is recommended by the American College of Obstetrics and Gynecologists that pelvic examinations be performed when indicated by medical history or symptoms and that the decision to perform a pelvic exam should be a shared decision between the patient and her clinician.
2. Breast exam for women 21 and older
3. Skin assessment
4. Thyroid assessment
5. Heart assessment
6. Lung assessment
7. Abdomen/GI assessment
8. GU exam
9. Lower extremities assessment
10. EENT assessment
11. Neurological assessment
12. Lymphatic assessment

LABORATORY

Should include:

Effective Date: 10/1/2024

Last Reviewed: 9/20/2024

Next Scheduled Review: 10/1/2025

1. Pap/HPV screening per current guidelines and recommendations; reference protocol GYN 1 and recommendations per ASCCP.
2. Offer and encourage Chlamydia/gonorrhea screening for women following CDC screening guidance.
3. HIV/other STI screening following CDC screening guidance.
4. Pregnancy testing if clinically indicated
5. Vaginal infection screening, if indicated

May Include as indicated:

1. Diabetes screening
2. Lipid panel
3. Hepatitis-C
4. Other lab tests based on clinical findings

ASSESSMENT

Annual Exam

PLAN

Should include:

1. Provision of contraceptive method chosen
2. Follow up of abnormal cervical cytology per ASCCP guidelines
3. Treatment of positive STI findings per CDC guidelines; reference protocols RD1, RD2, RD5, RD6, RD10, RD11

May Include as indicated:

1. Mammogram screening referral as per national recommendations including ACOG, ACS, and USPSTF using shared decision making and evaluating patient risk factor and history
2. Nicotine cessation counseling and referral
3. Education regarding the human papilloma virus vaccine

CLIENT EDUCATION

Should include:

1. Education per nationally recognized standards of care
2. Education on pregnancy and STI prevention

May include as indicated:

1. Education on Breast self-awareness
2. Healthy lifestyle choices including diet, exercise, and risk reduction
3. Immunization education and updates
4. Education on bone mineral density testing within 2 years of onset of menopause USPSTF: Grade B recommendation to screen at 65 and older
5. Education on colon cancer screening

CONSULT / REFER TO PHYSICIAN

1. Women with identified risks for BRCA 1 or BRCA 2 genetic mutations for genetic counseling and evaluation.

REFERENCES

1. Well-woman visit. ACOG Committee Opinion No. 755. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2018;132:e181–86. Retrieved from [Well-Woman Visit | ACOG \(2018\)](#)
2. The initial reproductive health visit. ACOG Committee Opinion No. 811. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2020;136:e70–80. Retrieved from [The Initial Reproductive Health Visit | ACOG \(2020\)](#)

Effective Date: 10/1/2024

Last Reviewed: 9/20/2024

Next Scheduled Review: 10/1/2025

3. Gavin L, Pazol K, Ahrens K. Update: Providing Quality Family Planning Services — Recommendations from CDC and the U.S. Office of Population Affairs, 2017. MMWR Morb Mortal Wkly Rep 2017;66:1383–1385. DOI: <http://dx.doi.org/10.15585/mmwr.mm6650a4> Update: Providing Quality Family Planning Services — Recommendations from CDC and the U.S. Office of Population Affairs, 2017 | MMWR
4. The utility of and indications for routine pelvic examination. ACOG Committee Opinion No. 754. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e174–80. Retrieved from <https://www.acog.org/-/media/project/acog/acogorg/clinical/files/committee-opinion/articles/2018/10/the-utility-of-and-indications-for-routine-pelvic-examination.pdf>
5. Marcus, Jenna Z. MD; Cason, Patty RN, MS, FNP-BC; Downs, Levi S. Jr. MD, MS; Einstein, Mark H. MD, MS; Flowers, Lisa MD. The ASCCP Cervical Cancer Screening Task Force Endorsement and Opinion on the American Cancer Society Updated Cervical Cancer Screening Guidelines. Journal of Lower Genital Tract Disease 25(3):p 187-191, July 2021. | DOI: 10.1097/LGT.0000000000000614. Retrieved from https://journals.lww.com/jlgt/Fulltext/2021/07000/The_ASCCP_Cervical_Cancer_Screening_Task_Force.1.aspx
6. U.S. Centers for Disease Control and Prevention. (2024). Screening recommendations and considerations referenced in treatment guidelines and original sources. Retrieved from <https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm>
7. U.S. Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR recommendations and reports; (70)4. Retrieved from <https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf>

Effective Date: 10/1/2024

Last Reviewed: 9/20/2024

Next Scheduled Review: 10/1/2025